CL2008002911A1 - Compuestos derivados de [arilo heteroarilo]-[1-piperidinilo susutituido]metanona, antagonista del receptor ccr-2, ccr-3, ccr-5; proceso de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de la enfermedad arterial periferica oclusiva e isquemia critica de las extremidades, entre otras. - Google Patents

Compuestos derivados de [arilo heteroarilo]-[1-piperidinilo susutituido]metanona, antagonista del receptor ccr-2, ccr-3, ccr-5; proceso de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de la enfermedad arterial periferica oclusiva e isquemia critica de las extremidades, entre otras.

Info

Publication number
CL2008002911A1
CL2008002911A1 CL2008002911A CL2008002911A CL2008002911A1 CL 2008002911 A1 CL2008002911 A1 CL 2008002911A1 CL 2008002911 A CL2008002911 A CL 2008002911A CL 2008002911 A CL2008002911 A CL 2008002911A CL 2008002911 A1 CL2008002911 A1 CL 2008002911A1
Authority
CL
Chile
Prior art keywords
ccr
pharmaceutical composition
treatment
methanone
extremities
Prior art date
Application number
CL2008002911A
Other languages
English (en)
Inventor
Binggeli Alfred
Ricklin Fabienne
Aebi Johannes
Green Luke
Hartmann Guido
P Maerki Hans
Mattei Patrizio
Roche Oliver
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40139996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002911(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2008002911A1 publication Critical patent/CL2008002911A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Compuestos derivados de aril o heteroaril carbonil heteroarilo, antagonistas de receptores ccr-2, ccr-3 y ccr-5, proceso de elaboración, composición farmacéutica y su uso en el tratamiento y/o prevención de la enfermedad arterial periférica oclusiva e isquemia crítica de las extremidades, entre otras.
CL2008002911A 2007-10-01 2008-09-30 Compuestos derivados de [arilo heteroarilo]-[1-piperidinilo susutituido]metanona, antagonista del receptor ccr-2, ccr-3, ccr-5; proceso de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de la enfermedad arterial periferica oclusiva e isquemia critica de las extremidades, entre otras. CL2008002911A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07117656 2007-10-01

Publications (1)

Publication Number Publication Date
CL2008002911A1 true CL2008002911A1 (es) 2010-01-04

Family

ID=40139996

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002911A CL2008002911A1 (es) 2007-10-01 2008-09-30 Compuestos derivados de [arilo heteroarilo]-[1-piperidinilo susutituido]metanona, antagonista del receptor ccr-2, ccr-3, ccr-5; proceso de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de la enfermedad arterial periferica oclusiva e isquemia critica de las extremidades, entre otras.

Country Status (15)

Country Link
US (1) US8153805B2 (es)
EP (1) EP2205583A2 (es)
JP (1) JP2010540584A (es)
KR (1) KR20100050570A (es)
CN (1) CN101801952A (es)
AR (1) AR068639A1 (es)
AU (1) AU2008307158A1 (es)
BR (1) BRPI0817935A2 (es)
CA (1) CA2700691A1 (es)
CL (1) CL2008002911A1 (es)
MX (1) MX2010003621A (es)
PE (1) PE20090775A1 (es)
RU (1) RU2010116821A (es)
TW (1) TW200920368A (es)
WO (1) WO2009043747A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5603770B2 (ja) 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
US8242145B2 (en) * 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
EP2268611A2 (en) * 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
EP2307362A4 (en) * 2008-07-03 2012-05-09 Panmira Pharmaceuticals Llc ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
WO2010077624A1 (en) * 2008-12-09 2010-07-08 Merck Sharp & Dohme Corp. Biaryl carboxamides
EP2379525B1 (en) 2008-12-19 2015-07-29 Boehringer Ingelheim International GmbH Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
ES2470329T3 (es) * 2009-08-28 2014-06-23 Daiichi Sankyo Company, Limited Derivado del ácido 3-(biariloxi) priopi�nico
US8471004B2 (en) * 2009-10-07 2013-06-25 Hoffman-La Roche Inc. Bicyclic compounds
MX2012006964A (es) 2009-12-17 2012-07-17 Boehringer Ingelheim Int Nuevos antagonistas del receptor ccr2 y usos de los mismos.
US20130143905A1 (en) * 2009-12-17 2013-06-06 Boehringer Ingelheim International Gmbh Novel antagonists for ccr2 and uses thereof
AU2011203649A1 (en) 2010-01-06 2012-06-14 Brickell Biotech, Inc. DP2 antagonist and uses thereof
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
JP5636094B2 (ja) * 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
EP2576538B1 (en) * 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
EP3143005B1 (en) * 2014-05-16 2021-07-07 Emory University Chemokine cxcr4 and ccr5 receptor modulators and used related thereto
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
BR112017028492B1 (pt) 2015-07-02 2023-12-26 Centrexion Therapeutics Corporation Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica
AU2017273857B2 (en) 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2538950A1 (de) 1975-09-02 1977-03-03 Basf Ag Verfahren zur herstellung von 2,6- dichlor-nicotinsaeuren
JPS5334790A (en) * 1976-09-13 1978-03-31 Yamanouchi Pharmaceut Co Ltd Novel nitrosourea derivatives and their preparation
PT650476E (pt) * 1993-04-07 2002-11-29 Otsuka Pharma Co Ltd Agente vasodilatador periferico que contem derivados n-acilados de 4-amino-piperidina como ingredientes activos
US6689765B2 (en) * 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
RU2299206C9 (ru) * 1999-05-04 2007-11-20 Шеринг Корпорейшн Производные пиперазина, фармацевтические композиции, их содержащие, и применение в качестве антагонистов ccr5
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
CN1182114C (zh) * 2000-05-01 2004-12-29 先灵公司 用作ccr5拮抗剂的哌嗪衍生物
US6670364B2 (en) * 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
IL157995A0 (en) * 2001-03-20 2004-03-28 Applied Research Systems The use of pyrrolidine ester derivatives in modulation of oxytoxin activity, some new such derivatives, their preparation and pharmaceutical compositions containing them
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds
WO2004043925A2 (en) 2002-11-08 2004-05-27 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
DE602005018758D1 (de) * 2004-04-01 2010-02-25 Lilly Co Eli Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
GB0418830D0 (en) * 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
US7820699B2 (en) * 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
ZA200709626B (en) * 2005-05-13 2009-02-25 Lexicon Pharmaceuticals Inc Multicyclic compounds and methods of their use
JP2009533416A (ja) * 2006-04-12 2009-09-17 ファイザー・リミテッド ケモカインｃｃｒ５受容体の調節剤としてのピロリジン誘導体
EP2099454A4 (en) * 2006-11-17 2010-11-10 Abbott Lab AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
CN101255134A (zh) * 2008-04-08 2008-09-03 温州医学院 芳基吡啶类化合物及其药物用途

Also Published As

Publication number Publication date
JP2010540584A (ja) 2010-12-24
RU2010116821A (ru) 2011-11-10
KR20100050570A (ko) 2010-05-13
AR068639A1 (es) 2009-11-25
US8153805B2 (en) 2012-04-10
BRPI0817935A2 (pt) 2015-04-07
PE20090775A1 (es) 2009-06-24
TW200920368A (en) 2009-05-16
MX2010003621A (es) 2010-04-14
EP2205583A2 (en) 2010-07-14
CN101801952A (zh) 2010-08-11
CA2700691A1 (en) 2009-04-09
AU2008307158A1 (en) 2009-04-09
WO2009043747A2 (en) 2009-04-09
WO2009043747A3 (en) 2009-07-23
US20090048238A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
CL2008002911A1 (es) Compuestos derivados de [arilo heteroarilo]-[1-piperidinilo susutituido]metanona, antagonista del receptor ccr-2, ccr-3, ccr-5; proceso de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de la enfermedad arterial periferica oclusiva e isquemia critica de las extremidades, entre otras.
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
GT200600081A (es) Derivados de acetilenno
UY27732A1 (es) Uso de análogos del benzimidazol en el tratamiento de la proliferación celular.
EA201070169A1 (ru) 2,3-дигидробензо[1,4]диоксин-2-илметиловые производные в качестве альфа2с антагонистов для применения в лечении заболеваний перифирической центральной нервной системы
UY28936A1 (es) Grupo de compuestos benzoil-amino-heterociclilo y composiciones farmaceuticas que los comprenden, utiles para tratamiento de enfermedades mediadas por glucoquinasa (gq)
EA201071291A2 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
ECSP10010585A (es) Compuestos de 2- imido- 3- metil pirrolo pirimidinona fenilo- sustituidos como inhibidores bace- 1, composiciones, y su uso
CL2012003421A1 (es) Compuestos derivados de 3-amino-n-(4-carbamoilpiridin-3-il)(aril/heteroaril)-2-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad del snc, oncologica, entre otras. pct fase nacional
CL2012002771A1 (es) Compuestos derivados de ariletinilo sustituidos, moduladores de los receptores mglur5; proceso de obtencion; composicion farmaceutica; y su uso en el tratamiento o prevencion de la esquizofrenia, enfermedades cognitivas, sindrome de x fragil o el autismo.
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
NI200700237A (es) Proceso para la preparación de moduladores de opioides
DE602008003322D1 (de) Pyrrolo (3, 2, 1-ij) chinolin-4-on-derivate zur behandlung von tuberkulose
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
ECSP088270A (es) Derivados de (indol-3-il)-heterociclo como agonistas del receptor cannabinoide cb1
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo